Synovial Sarcoma Foundation Hosts Second Community Webinar Highlighting Research Momentum
On February 19, 2026, the Synovial Sarcoma Foundation brought together patients, families, clinicians, and researchers from around the world for…
Rethinking the Driver: New Research Identifies P300 as a Critical Co-Factor in Synovial Sarcoma
Synovial sarcoma is driven by a defining genetic event — the SS18-SSX fusion protein, present in nearly all cases. For…
Synovial Sarcoma Treatment Market Projected to Grow Through 2031: What This Means for Patients
A recent market analysis estimates that the global synovial sarcoma treatment market was valued at approximately $832 million in 2023…
Join the Upcoming Synovial Sarcoma Webinar
Join the Synovial Sarcoma Foundation for a live, one-hour webinar focused on where synovial sarcoma research is heading and what…
Synovial Sarcoma of the Parotid Gland in Infancy: A Rare Case Study
Synovial sarcoma most often develops near the large joints of the arms or legs, but in rare cases it can…
Monophasic Synovial Sarcoma of the Posterior Pharyngeal Wall: A Rare Case Study
Content Warning:This article references a published medical case study that includes graphic surgical images involving the head and neck region.…
UI Health Care Begins Treating Patients With TCR Therapy for Synovial Sarcoma
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T…
Prasterone (DHEA) for Metastatic or Unresectable Synovial Sarcoma
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread…
Celebrating Milestones with Hope: The 100th Sign-Up for the Synovial Sarcoma Registry and Biospecimen Repository
We are thrilled to announce a significant milestone for the Synovial Sarcoma Registry and Biospecimen Repository, as we proudly welcome…